These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24757092)

  • 1. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
    Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
    Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
    Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
    Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
    Todaro J; Bollmann PW; Rother ET; del Giglio A
    Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
    Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
    Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
    Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
    Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
    Goodyear OC; Dennis M; Jilani NY; Loke J; Siddique S; Ryan G; Nunnick J; Khanum R; Raghavan M; Cook M; Snowden JA; Griffiths M; Russell N; Yin J; Crawley C; Cook G; Vyas P; Moss P; Malladi R; Craddock CF
    Blood; 2012 Apr; 119(14):3361-9. PubMed ID: 22234690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.
    Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X
    Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
    Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
    J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
    Scott GB; Carter C; Parrish C; Wood PM; Cook G
    Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
    Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.
    Pollyea DA; Kohrt HE; Gallegos L; Figueroa ME; Abdel-Wahab O; Zhang B; Bhattacharya S; Zehnder J; Liedtke M; Gotlib JR; Coutre S; Berube C; Melnick A; Levine R; Mitchell BS; Medeiros BC
    Leukemia; 2012 May; 26(5):893-901. PubMed ID: 22033493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
    Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
    Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation.
    Schroeder T; Fröbel J; Cadeddu RP; Czibere A; Dienst A; Platzbecker U; Bug G; Uharek L; Fenk R; Germing U; Kröger N; Haas R; Kobbe G
    Leukemia; 2013 Sep; 27(9):1910-3. PubMed ID: 23519388
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.